La vendita allo scoperto per 60 Degrees dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di 60 Degrees. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

60 Degrees (NASDAQ:SXTP) Azioni, Report sulle vendite allo scoperto

60 Degrees

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

Envoy Medical, Inc. - Class A Common Stock

COCH

HYLN

SXTP

Scopri le penny stock sotto i $5 in cui Hyliion e altri due titoli stanno attirando l&#39;attenzione degli insider.

Penny stock sotto i $5: Hyliion e altri 2 titoli sotto osservazione

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals, Inc. - Warrant

CoreWeave, a fast-growing cloud startup that operates data centers for artificial intelligence developers, pitches itself to investors as a nimble rival to behemoths like Microsoft, Amazon and Alphabet. And yet the speed of CoreWeave's rise has only been possible thanks to its relationship with one of the giants it says it's trying to slay. Microsoft plans to spend about $10 billion between 2023 and the end of the decade using the startup's data centers to run artificial intelligence models, CoreWeave told investors recently, a larger commitment than was previously known. Microsoft is likely CoreWeave's biggest customer by a significant margin, as the startup also told investors the total value of its signed contracts are $17 billion, without specifying the time period.
<a href="https://www.theinformation.com/articles/microsoft-is-a-coreweave-rival-its-also-a-big-customer" title="https://www.theinformation.com/articles/microsoft-is-a-coreweave-rival-its-also-a-big-customer">https://www.theinformation.com/articles/microsoft-is-a-coreweave-rival-its-also-a-big-customer</a>

MSFT

'Microsoft Is a CoreWeave Rival. It's Also a Big Customer' - The Information

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Friday.
The Dow traded up 0.67% to 42,043.38 while the NASDAQ surged 0.75% to 18,230.53. The S&amp;P 500 also rose, gaining, 0.47% to 5,732.21.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41653495/top-2-real-estate-stocks-you-may-want-to-dump-this-quarter">Top 2 Real Estate Stocks You May Want To Dump This Quarter</a>
Leading and Lagging Sectors Consumer discretionary shares rose by 2.3% on Friday.
In trading on Friday, utilities shares fell by 2.1%.
Top Headline
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares fell around 2% on Friday after the company reported results for the fourth quarter.
The company reported fiscal fourth-quarter revenue of $94.9 billion, beating analyst estimates of $94.56 billion. The iPhone maker reported fourth-quarter adjusted earnings of $1.64 per share, beating analyst estimates of $1.60 per share.
<h3 class="wp-block-heading">Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares shot up 53% to $5.34 after the company reported a year-over-year increase in third-quarter EPS results and raised its FY24 revenue guidance.</li>
<li>Shares of Proto Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLB#NASDAQ">PRLB</a>) got a boost, surging 33% to $36.42 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter adjusted EPS guidance with its midpoint above estimates.</li>
<li>Interface, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TILE#NASDAQ">TILE</a>) shares were also up, gaining 33% to $23.23 after the company reported better-than-expected third-quarter financial results and raised its FY24 net sales guidance above estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ESSA Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPIX#NASDAQ">EPIX</a>) shares dropped 71% to $1.51 after the company announced it terminated its Phase 2 study evaluating masofaniten combined with enzalutamide in patients with mCRPC.</li>
<li>Shares of Myriad Genetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) were down 21% to $17.30. Myriad Genetics will hold its third quarter earnings conference call on Thursday, Nov. 7.</li>
<li>Lexicon Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) was down, falling 37% to $1.2250. Lexicon Pharmaceuticals announced the outcome of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Meeting to review the company's New Drug Application (NDA) for Zynquista (sotagliflozin). The company is seeking approval for the oral SGLT1/SGLT2 inhibitor as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD).</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $69.79 while gold traded down 0.1% at $2,745.60.
Silver traded down 0.7% to $32.555 on Friday, while copper rose 0.3% to $4.3520.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.09%, Germany's DAX gained 0.93% and France's CAC 40 gained 0.80%. Spain's IBEX 35 Index surged 1.46%, while London's FTSE 100 rose 0.83%.
Asia Pacific Markets
Asian markets closed mostly lower on Friday, with Japan's Nikkei 225 falling 2.63%, Hong Kong's Hang Seng Index gaining 0.93%, China's Shanghai Composite Index declining 0.24% and India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>The U.S. economy added 12,000 jobs in October compared to a revised 223,000 gain in September and versus market estimates of 113,000.</li>
<li>Average hourly earnings increased by 0.4% over a month to $35.46 in October, while unemployment rate came in unchanged at 4.1% in October.</li>
<li>U.S. construction spending increased by 0.1% month-over-month to an annual rate of $2,148.8 billion in September.</li>
<li>The S&amp;P Global Flash manufacturing PMI was revised upward to 48.5 in October versus a preliminary reading of 47.8.</li>
<li>The ISM manufacturing PMI declined to 46.5 in October versus 47.2 in the previous month and down from estimates of 47.6.</li>
<li>The total number of active U.S. oil rigs fell by one to 479 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="Top%202%20Utilities%20Stocks%20That%20May%20Crash%20This%20Quarter">Top 2 Utilities Stocks That May Crash This Quarter</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

AAPL

CDXC

EPIX

LXRX

MYGN

PRLB

TILE

Crude Oil Moves Higher; Apple Shares Slide After Q4 Results

WIIM

Alliant Energy shares are trading lower. The company reported Q3 financial results.

Generac Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) reported better-than-expected earnings for its <a href="https://www.benzinga.com/quote/GNRC/earnings">fourth quarter on Thursday</a>.
The company posted quarterly earnings of $2.25 per share which beat the analyst consensus estimate of $1.95 per share. The company reported quarterly sales of $1.173 billion which beat the analyst consensus estimate of $1.161 billion.
&#8220;Our third quarter results outperformed our expectations as elevated power outage activity drove increased shipments of our residential products and strong execution helped to deliver significant margin expansion,&#8221; said Aaron Jagdfeld, President and Chief Executive Officer. &#8220;Shipments of home standby and portable generators increased at a very strong rate from the prior year period, more than offsetting expected softness in C&amp;I product sales. As a result, we are updating our full year 2024 guidance to include higher residential product sales with further improvements in adjusted EBITDA margins.&#8221;
Generac shares gained 2.4% to trade at $169.47 on Friday.
These analysts made changes to their price targets on Generac following earnings announcement.
<ul>
<li>Baird analyst Michael Halloran maintained Generac with a Neutral and lowered the price target from $187 to $181.</li>
<li>Goldman Sachs analyst Jerry Revich maintained the stock with a Buy and raised the price target from $148 to $193.</li>
<li>TD Cowen analyst Jeffrey Osborne maintained Generac with a Buy and raised the price target from $172 to $183.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Price Target

Analyst Ratings

GNRC

These Analysts Revise Their Forecasts On Generac After Q4 Results

Wells Fargo analyst Michael Turrin maintains Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) with a Equal-Weight and raises the price target from $75 to $80.

TWLO

Wells Fargo Maintains Equal-Weight on Twilio, Raises Price Target to $80

PCTY

Paylocity Holding shares are trading higher after Truist Securities maintained a Buy rating on the stock and raised its price target from $195 to $210.

On Thursday,&nbsp;Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/earnings-beats/24/10/41655506/merck-beats-q3-estimates-but-lowers-annual-forecast-as-gardasil-vaccine-hit-by-low-c" rel="noreferrer noopener">consensus of $16.47 billion</a>.
Merck reported a decline of 11% in sales of Gardasil to $2.31 billion, a vaccine that prevents cancer from HPV, the most common sexually transmitted infection in the U.S., due to lower demand in China, partially offset by higher sales in the U.S., driven by public-sector buying patterns, higher pricing and demand, and higher demand in most international regions.
Beyond Gardasil, Goldman Sachs highlights a solid lineup of positives for Merck, including robust performance from key franchises like Keytruda and promising momentum from both commercial products like Winrevair and Capvaxive and development-stage innovations such as clesrovimab and tulisokobart.
Merck's blockbuster cancer immunotherapy Keytruda generated&nbsp;$7.43 billion&nbsp;in revenue during the quarter, up 17% from the year-earlier period.&nbsp;
The newly approved Winrevair (sotatercept) for adults with pulmonary arterial hypertension generated&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37958211/mercks-11b-bet-pays-as-fda-approves-sotatercept-for-rare-lung-disease" rel="noreferrer noopener">sales of $149 million</a>.
Goldman reiterates the Buy rating for Merck stock, decreasing the price target from $139 to $135, reflecting lowered <a target="_blank" href="https://www.benzinga.com/quote/MRK/analyst-ratings" rel="noreferrer noopener">resetting of Gardasil forecasts</a>.
BMO Capital Markets suggests that Merck's Gardasil sales in China may continue to be challenging through 2025.
Although Merck does not provide specific product-level forecasts, CEO Rob Davis offered some perspective, anticipating Gardasil sales in China could reach around $2 billion to $3 billion in 2025.
Winrevair continues to show strong performance, driven by organic demand. According to a BMO analyst, there was some initial skepticism about the organic demand for Winrevair after comments regarding stocking in Q2 2024.
However, the recent performance data has restored confidence, indicating that the drug is experiencing sustained demand growth, with an uptake of approximately 80% for the quarter.
This trend is expected to continue into 2025, particularly with the forthcoming ZENITH and CADENCE trials.
BMO cut the price target from $150 to $136, with an Outperform rating.
Price Action: MRK stock is down 0.22% at $102.07&nbsp;at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41689161/wayfair-q3-results-earnings-beat-street-but-sales-and-customer-base-decline" target="_blank" rel="noreferrer noopener">Wayfair Q3 Results: Earnings Beat Street, But Sales And Customer Base Decline</a></li>
</ul>
Image via Merck

Analyst Color

Biotech

Large Cap

Health Care

General

Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease

TD Cowen analyst Jeffrey Osborne maintains Nikola (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) with a Hold and lowers the price target from $10 to $4.

NKLA

TD Cowen Maintains Hold on Nikola, Lowers Price Target to $4

Wells Fargo analyst Ken Gawrelski maintains Etsy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) with a Underweight and lowers the price target from $47 to $44.

ETSY

Wells Fargo Maintains Underweight on Etsy, Lowers Price Target to $44

LECO

Lincoln Electric shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

TD Cowen analyst Jeffrey Osborne maintains Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Buy and lowers the price target from $95 to $74.

APTV

TD Cowen Maintains Buy on Aptiv, Lowers Price Target to $74

Imperial Oil shares are trading lower after the company reported mixed Q3 financial results.

CTRA

Corterra Energy shares are trading lower after the company reported worse-than-expected Q3 adjusted EPS results and cut its FY24 capital expenditure.

B of A Securities analyst Bryan Spillane maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Neutral and lowers the price target from $100 to $75.

B of A Securities Maintains Neutral on Estee Lauder Cos, Lowers Price Target to $75

UBS analyst Jay Sole maintains Kontoor Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KTB#NYSE">KTB</a>) with a Buy and raises the price target from $103 to $110.

UBS Maintains Buy on Kontoor Brands, Raises Price Target to $110

Dayforce shares are trading higher after BMO Capital maintained an Outperform rating on the stock and raised its price target from $70 to $80.

Service Corp International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) reported better-than-expected third-quarter adjusted <a href="https://www.benzinga.com/quote/SCI/earnings">EPS results on Thursday</a>.
Service Corp Intl reported quarterly earnings of 79 cents per share beat the analyst consensus estimate of 77 cents per shsare. The company reported quarterly sales of $1.014 billion which missed the analyst consensus estimate of $1.016 billion.
Tom Ryan, the Company&#8217;s Chairman and CEO, commented, &#8220;Today we reported adjusted earnings per share of $0.79 and net cash provided by operating activities excluding special items of $269 million. We are excited to see the positive impact in funeral revenue from our new marketing agreement with our new preferred preneed insurance provider, which launched during the quarter. Additionally, we are pleased both funeral and cemetery gross profit were relatively stable versus the prior year third quarter with modest revenue growth reflecting our continued focus on managing fixed costs.&#8221;
Service Corp Intl said it sees fourth-quarter adjusted loss of $1.00-1.10 per share, versus estimates of 77 cents per share.
Service Corp International shares gained 0.2% to trade at $81.79 on Friday.
These analysts made changes to their price targets on Service Corp International following earnings announcement.
<ul>
<li>Raymond James analyst John Ransom maintained Service Corp Intl with an Outperform and increased the price target from $80 to $85.</li>
<li>Truist Securities analyst Tobey Sommer maintained the stock with a Buy and raised the price target from $84 to $92.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41685620/top-3-energy-stocks-that-are-preparing-to-pump-in-november">Top 3 Energy Stocks That Are Preparing To Pump In November</a></li>
</ul>

Service Corp International Analysts Boost Their Forecasts After Upbeat Earnings

TD Cowen analyst Jeffrey Osborne maintains Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with a Buy and raises the price target from $172 to $183.

TD Cowen Maintains Buy on Generac Hldgs, Raises Price Target to $183

UBS analyst Eliana Merle maintains Madrigal Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDGL#NASDAQ">MDGL</a>) with a Buy and raises the price target from $411 to $441.

MDGL

UBS Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $441

TD Cowen analyst Jeffrey Osborne maintains Itron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRI#NASDAQ">ITRI</a>) with a Buy and raises the price target from $125 to $136.

ITRI

TD Cowen Maintains Buy on Itron, Raises Price Target to $136

In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report)...

H.C. Wainwright Keeps Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
60 Degrees Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) stock is gaining on Monday after the specialty pharmaceutical company <a href="https://finance.yahoo.com/news/60-degrees-pharma-provides-university-131200159.html">announced an agreement</a> with the University of Kentucky.



This agreement will have the University of Kentucky conducting a Phase IIb clinical trial of SJ733. This is a drug candidate in development by 60 Degrees Pharmaceuticals for the treatment of vivax malaria.



This study will cover the use of SJ733 alongside tafenoquine to treat vivax malaria. The information from this study will also be applied to 60 Degrees Pharmaceuticals New Drug Application (NDA) for the drug.



Dr. R. Kip Guy, the principal investigator of the study, said the following about it:




&ldquo;Innovations in treating P. vivax malaria, which infects an estimated 14 million people a year, have been limited in recent decades. The upcoming study of SJ733 combined with tafenoquine has the potential to pave the way for very meaningful improvement in malaria treatment around the world.&rdquo;




<h2>What This Means for SXTP Stock</h2>



This new clinical trial news has SXTP stock heading higher on Monday with heavy trading of the shares. That has more than 11.9 million shares changing hands as of this writing. To put that in perspective, the company&rsquo;s daily average trading volume is about 448,000 shares.



SXTP stock is up 28.9% as of Monday afternoon.



There are even more stock market stories traders are going to want to read about below!



We have all of the hottest stock market news ready to go on Monday! A few examples include what&rsquo;s going on with shares of Draganfly&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/dpro-stock-quote/">DPRO</a>), KeyBank (NYSE:<a href="https://investorplace.com/stock-quotes/key-stock-quote/">KEY</a>) and Archer Aviation&nbsp;(NYSE:<a href="https://investorplace.com/stock-quotes/achr-stock-quote/">ACHR</a>) stock today. All of this news is available at the following links!



<h2>More Monday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/08/why-is-draganfly-dpro-stock-up-37-today/">Why Is Draganfly (DPRO) Stock Up 37% Today?</a></li>



<li><a href="https://investorplace.com/2024/08/key-stock-surge-alert-whats-going-on-with-keycorp-shares-today/">KEY Stock Surge Alert: What&rsquo;s Going On With KeyCorp Shares Today?</a></li>



<li><a href="https://investorplace.com/2024/08/achr-stock-3-things-for-investors-to-know-about-the-370-million-stellantis-deal/">ACHR Stock: 3 Things for Investors to Know About the $370 Million Stellantis Deal</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/why-is-60-degrees-pharmaceuticals-sxtp-stock-up-29-today/">Why Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) just reported results for the second quarter of 2024.<ul><li>60 Degrees reported earnings per share of -$4.23. This was below the analyst estimate for EPS of -23 cents.</li><li>The company reported revenue of $124,972.</li><li>This was 37.51% worse than the analyst estimate for revenue of $200,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/sxtp-stock-earnings-60-degrees-for-q2-of-2024/">SXTP Stock Earnings: 60 Degrees Misses EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SXTP Stock Earnings: 60 Degrees Misses EPS, Misses Revenue for Q2 2024

H.C. Wainwright Sticks to Their Hold Rating for 60 Degrees Pharmaceuticals, Inc. (SXTP)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Outlook Therapeutics (OTLK – Research Report), 60 ...

Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Gritstone Oncology (GRTS)

60 Degrees Pharmaceuticals GAAP EPS of -$4.23

Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more

60 Degrees Pharmaceuticals to raise $4M via private placement; shares fall

H.C. Wainwright analyst Edward White maintained a Hold rating on 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report) today. The company's sha...

H.C. Wainwright Reaffirms Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)

Warning: SXTP is at high risk of performing badly

ASND

AYRO

BIDU

BILI

BTBT

CARA

CATO

COTY

CSIQ

CTXR

ESTC

FORD

FUTU

GGAL

GRTS

IMMR

INTU

JKHY

KEYS

MBRX

MMAT

NNDM

NNOX

NTES

OTLK

PANW

PTON

ROST

SEEL

SNOW

SNPS

URBN

VIPS

WDAY

WKHS

WOLF

XPEV

Press Releases

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

Contracts

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Financing

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Comments

60 Degrees

Vendite allo scoperto

60 Degrees (NASDAQ:SXTP) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO